Clinical trial · Observational
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
Global PANORAMA Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Cancelled due to changes in the scientific landscape. Decision was made after thorough evaluation of of pros\&cons, ethical as well as regulatory consideration
Summary
Brief summary (as posted)
This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer). Patients will be recruited from participating sites in Europe, Asia, and Canada. The study will include 2 patient cohorts.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient Reported Outcomes | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with EGFR mutation (+) NSCLC
- description
- Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
- interventionNames
- Other: Patient Reported Outcomes
- label
- Patients newly diagnosed NSCLC
- description
- Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
- interventionNames
- Other: Patient Reported Outcomes
Primary outcomes (2)
- measure
- Parameters in the target population associate with molecular testing patters
- timeFrame
- Patients will be followed from enrolment in the study until death, loss to follow-up, withdrawal of consent or study end date. The minimum follow-up will be 12 months and the maximum allowed follow-up will be 36 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent - patient consent should be within 6 weeks of index date. * Adult male or female subjects (according to age of majority/adulthood as defined by local regulations) Exclusion Criteria: -Enrolment in studies that prohibit any participation in this non interventional study
References
Publications (0)
Data not yet available